NCT07879885 An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
| NCT ID | NCT07879885 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hansoh BioMedical R&D Company |
| Condition | Moderate-to-severe Plaque Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 390 participants |
| Start Date | 2025-07-31 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 390 participants in total. It began in 2025-07-31 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 and above, male or female; 2. Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis; 3. During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥3%; b) PASI≥3; 4. Voluntarily participate in the research, have the ability and willingness to complete the research according to the research protocol, and sign the informed consent. Exclusion Criteria: 1. History of an allergic reaction following prior use of a biologic agent, allergy to known drug components, or a history of severe food or drug allergy; 2. Confirmation of other types of psoriasis, including but not limited to guttiform psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced exacerbation of psoriasis (including beta-blockers, non-steroidal anti-inflammatory drugs, antimalarial drugs, interferon, calcium channel blockers, or lithium induced psoriasis) from the screening period to the time before the first dose; 3. Other skin lesions, chronic inflammatory diseases or autoimmune diseases, including but not limited to systemic lupus erythematosus, Sjogren's syndrome, skin sclerosis, etc., assessed by the investigator and other factors that may affect the efficacy evaluation or assessed by other researchers before the first dose; 4. Primary treatment failure occurred with previous use of similar investigatory drugs (including marketed ulinumab, gusecciumab, Tiricizumab, Lisenciumab, and IL-23 target investigatory drugs under development) (the minimum treatment standard was not reached 12 weeks after the first treatment); 5. Use of the following drugs before the first dose: 1. Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before the first dose; 2. 1 weeks before the first administration, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis; 3. Prior to the first dose, use of other biologics for the treatment of psoriasis (including but not limited to TNF α inhibitors, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, and investigational IL 23 targeting drugs) without meeting the protocol required time interval for re administration of the original biologic; 4. use of lymphocyte migration regulators or B cell and T cell regulators (including but not limited to abatacept, telitacicept, etc.), within 3 months before dose, or 6 months before screening, (whichever is older) use of B-cell-specific scavenging drugs (including but not limited to rituximab, inebilizumab, etc.); 6. A history of chronic recurrent infection, or opportunistic infection in the 6 months prior to screening, or hospitalization for a serious infectious disease or intravenous antibiotic use in the 2 months prior to randomization, with a confirmed or suspected illness in the 1 week prior to the first dose. And Other circumstances determined by the investigator to be unsuitable for further study participation.
Frequently Asked Questions
Who can join the NCT07879885 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Moderate-to-severe Plaque Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07879885 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07879885 currently recruiting?
Yes, NCT07879885 is actively recruiting participants. Visit ClinicalTrials.gov or contact Hansoh BioMedical R&D Company to inquire about joining.
Where is the NCT07879885 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07879885 clinical trial?
NCT07879885 is sponsored by Hansoh BioMedical R&D Company. The trial plans to enroll 390 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.